Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia.

COVID-19 cancer diabetes multiple sclerosis vaccine hesitancy

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
26 May 2022
Historique:
received: 10 05 2022
revised: 23 05 2022
accepted: 23 05 2022
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 25 6 2022
Statut: epublish

Résumé

As COVID-19 vaccinations became available and were proven effective in preventing serious infection, uptake amongst individuals varied, including in medically vulnerable populations. This cross-sectional multi-site study examined vaccine uptake, hesitancy, and explanatory factors amongst people with serious and/or chronic health conditions, including the impact of underlying disease on attitudes to vaccination. A 42-item survey was distributed to people with cancer, diabetes, or multiple sclerosis across ten Australian health services from 30 June to 5 October 2021. The survey evaluated sociodemographic and disease-related characteristics and incorporated three validated scales measuring vaccine hesitancy and vaccine-related beliefs generally and specific to their disease: the Oxford COVID-19 Vaccine Hesitancy Scale, the Oxford COVID-19 Vaccine Confidence and Complacency Scale and the Disease Influenced Vaccine Acceptance Scale-Six. Among 4683 participants (2548 [54.4%] female, 2108 [45.0%] male, 27 [0.6%] other; mean [SD] age, 60.6 [13.3] years; 3560 [76.0%] cancer, 842 [18.0%] diabetes, and 281 [6.0%] multiple sclerosis), 3813 (81.5%) self-reported having at least one COVID-19 vaccine. Unvaccinated status was associated with younger age, female sex, lower education and income, English as a second language, and residence in regional areas. Unvaccinated participants were more likely to report greater vaccine hesitancy and more negative perceptions toward vaccines. Disease-related vaccine concerns were associated with unvaccinated status and hesitancy, including greater complacency about COVID-19 infection, and concerns relating to vaccine efficacy and impact on their disease and/or treatment. This highlights the need to develop targeted strategies and education about COVID-19 vaccination to support medically vulnerable populations and health professionals.

Identifiants

pubmed: 35746458
pii: vaccines10060851
doi: 10.3390/vaccines10060851
pmc: PMC9230066
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Health Expect. 2000 Mar;3(1):6-16
pubmed: 11281907
Vaccines (Basel). 2021 Feb 16;9(2):
pubmed: 33669441
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Vaccines (Basel). 2021 Jul 16;9(7):
pubmed: 34358208
Expert Rev Vaccines. 2022 Apr;21(4):435-451
pubmed: 35112973
Hum Vaccin Immunother. 2013 Aug;9(8):1763-73
pubmed: 23584253
J Cancer Res Clin Oncol. 2022 Jun;148(6):1363-1374
pubmed: 35218401
Behav Med. 2022 Jun 15;:1-10
pubmed: 35703037
Psychol Med. 2020 Dec 11;:1-15
pubmed: 33305716
Mult Scler Relat Disord. 2021 Oct;55:103175
pubmed: 34343866
J Behav Med. 2022 Jan 15;:
pubmed: 35032254
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
JMIR Public Health Surveill. 2022 Jan 5;8(1):e29872
pubmed: 34709184
Front Psychol. 2020 Oct 19;11:575950
pubmed: 33192883
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Asia Pac J Clin Oncol. 2022 Jan 18;:
pubmed: 35043559
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Hum Vaccin Immunother. 2021 Nov 02;17(11):4048-4056
pubmed: 34357827
N Engl J Med. 2021 Oct 7;385(15):1355-1371
pubmed: 34496194
Healthcare (Basel). 2021 Mar 19;9(3):
pubmed: 33808758
Eur J Cancer. 2021 Aug;153:260-264
pubmed: 34183225

Auteurs

Daphne Day (D)

Department of Oncology, Monash Health, Clayton, VIC 3168, Australia.
Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC 3168, Australia.

Lisa Grech (L)

Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC 3168, Australia.

Mike Nguyen (M)

Department of Oncology, Monash Health, Clayton, VIC 3168, Australia.
Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC 3168, Australia.

Nathan Bain (N)

Department of Oncology, Monash Health, Clayton, VIC 3168, Australia.

Alastair Kwok (A)

Department of Oncology, Monash Health, Clayton, VIC 3168, Australia.
Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC 3168, Australia.

Sam Harris (S)

Department of Medical Oncology, Bendigo Health, Bendigo, VIC 3550, Australia.

Hieu Chau (H)

Department of Oncology, Latrobe Regional Hospital, Traralgon, VIC 3844, Australia.

Bryan Chan (B)

Department of Oncology, Sunshine Coast Hospital and Health Service, Birtinya, QLD 4575, Australia.
School of Medicine, Griffith University, Birtinya, QLD 4575, Australia.

Richard Blennerhassett (R)

Central Coast Haematology, North Gosford, NSW 2250, Australia.
School of Medicine and Public Health, University of Newcastle, Newcastle, NSW 2308, Australia.

Louise Nott (L)

Icon Cancer Centre Hobart, Hobart, TAS 7000, Australia.

Nada Hamad (N)

Department of Haematology, St Vincent's Hospital Sydney, Darlinghurst, NSW 2010, Australia.
School of Clinical Medicine, Faculty of Medicine & Health, University of New South Wales, Kensington, NSW 2052, Australia.
School of Medicine, University of Notre Dame Australia, Chippendale, NSW 2007, Australia.

Annette Tognela (A)

Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, NSW 2560, Australia.

David Hoffman (D)

Dr David Hoffman, Fairfield, NSW 2165, Australia.

Amelia McCartney (A)

Department of Oncology, Monash Health, Clayton, VIC 3168, Australia.
Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC 3168, Australia.

Kate Webber (K)

Department of Oncology, Monash Health, Clayton, VIC 3168, Australia.
Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC 3168, Australia.

Jennifer Wong (J)

Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC 3168, Australia.
Monash Diabetes, Monash Health, Clayton, VIC 3168, Australia.

Craig Underhill (C)

Border Medical Oncology, Albury, NSW 2640, Australia.
Rural Medical School, University of New South Wales, Albury, NSW 2640, Australia.

Brett Sillars (B)

Department of Endocrinology, Sunshine Coast Hospital and Health Service, Birtinya, QLD 4575, Australia.

Antony Winkel (A)

School of Medicine, Griffith University, Birtinya, QLD 4575, Australia.
Department of Neurology, Sunshine Coast Hospital and Health Service, Birtinya, QLD 4575, Australia.

Mark Savage (M)

Department of Endocrinology, Bendigo Health, Bendigo, VIC 3550, Australia.

Bao Sheng Loe (BS)

The Psychometrics Centre, University of Cambridge, Cambridge CB2 1AG, UK.

Daniel Freeman (D)

Department of Psychiatry, University of Oxford, Oxford OX3 7JX, UK.
Oxford Health National Health Service Foundation Trust, Oxford OX3 7JX, UK.

Eva Segelov (E)

Department of Oncology, Monash Health, Clayton, VIC 3168, Australia.
Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC 3168, Australia.

Classifications MeSH